CA3241845A1 - Compounds - Google Patents
CompoundsInfo
- Publication number
- CA3241845A1 CA3241845A1 CA3241845A CA3241845A CA3241845A1 CA 3241845 A1 CA3241845 A1 CA 3241845A1 CA 3241845 A CA3241845 A CA 3241845A CA 3241845 A CA3241845 A CA 3241845A CA 3241845 A1 CA3241845 A1 CA 3241845A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- synthesis
- treatment
- present disclosure
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904268 | 2021-12-24 | ||
| AU2021904268A AU2021904268A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051591 WO2023115165A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241845A1 true CA3241845A1 (en) | 2023-06-29 |
Family
ID=86900872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241845A Pending CA3241845A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250163044A1 (enExample) |
| EP (1) | EP4452979A4 (enExample) |
| JP (1) | JP2025501141A (enExample) |
| KR (1) | KR20240128059A (enExample) |
| CN (1) | CN118974044A (enExample) |
| AU (1) | AU2022422215A1 (enExample) |
| CA (1) | CA3241845A1 (enExample) |
| IL (1) | IL313857A (enExample) |
| MX (1) | MX2024007911A (enExample) |
| WO (1) | WO2023115165A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| EP4255422A4 (en) * | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| KR20240058859A (ko) | 2021-08-12 | 2024-05-03 | 쿨레온 엘엘씨 | 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법 |
| IL313455A (en) | 2021-12-15 | 2024-08-01 | Delix Therapeutics Inc | Phenoxy and benzyloxy modified psychroplastogens and their uses |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2025000053A1 (en) * | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Compounds |
| WO2025000051A1 (en) | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| WO2026030052A1 (en) | 2024-07-31 | 2026-02-05 | Fmc Corporation | Fungicidal substituted azoles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977131A (en) * | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| GB9819020D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| MXPA04011791A (es) * | 2002-05-30 | 2005-07-26 | Jesse A May | Piranoindazoles y su uso para el tratamiento de glaucoma. |
| US7964728B2 (en) * | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| IL266563B (en) * | 2009-10-06 | 2022-09-01 | Millennium Pharm Inc | Heterocyclic compounds useful as pdk1 inhibitors |
| EP2771341A4 (en) * | 2011-10-28 | 2015-09-23 | Univ Texas | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| KR20230066311A (ko) * | 2020-06-10 | 2023-05-15 | 델릭스 테라퓨틱스, 인크. | 삼환형 사이코플라스토겐 및 이의 용도 |
| EP4255422A4 (en) * | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| KR20240058859A (ko) | 2021-08-12 | 2024-05-03 | 쿨레온 엘엘씨 | 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법 |
-
2022
- 2022-12-23 CN CN202280091203.9A patent/CN118974044A/zh active Pending
- 2022-12-23 MX MX2024007911A patent/MX2024007911A/es unknown
- 2022-12-23 IL IL313857A patent/IL313857A/en unknown
- 2022-12-23 US US18/722,007 patent/US20250163044A1/en active Pending
- 2022-12-23 KR KR1020247024904A patent/KR20240128059A/ko active Pending
- 2022-12-23 WO PCT/AU2022/051591 patent/WO2023115165A1/en not_active Ceased
- 2022-12-23 JP JP2024538669A patent/JP2025501141A/ja active Pending
- 2022-12-23 CA CA3241845A patent/CA3241845A1/en active Pending
- 2022-12-23 EP EP22908927.1A patent/EP4452979A4/en active Pending
- 2022-12-23 AU AU2022422215A patent/AU2022422215A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007911A (es) | 2024-09-10 |
| KR20240128059A (ko) | 2024-08-23 |
| EP4452979A1 (en) | 2024-10-30 |
| CN118974044A (zh) | 2024-11-15 |
| US20250163044A1 (en) | 2025-05-22 |
| WO2023115165A1 (en) | 2023-06-29 |
| EP4452979A4 (en) | 2025-11-26 |
| JP2025501141A (ja) | 2025-01-17 |
| IL313857A (en) | 2024-08-01 |
| AU2022422215A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3241845A1 (en) | Compounds | |
| MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| MY147767A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| TW200736213A (en) | Dicarboxylic acid derivatives and their use | |
| EP4647121A3 (en) | Novel uses of piperidinyl-indole derivatives | |
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| TN2010000288A1 (en) | 4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof | |
| WO2015039612A8 (zh) | 抑制btk和/或jak3激酶活性的化合物 | |
| WO2009067493A3 (en) | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders | |
| TW200621765A (en) | Substituted phenylaminothiazoles and their use | |
| SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
| UA102238C2 (en) | 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof | |
| GB2557471A (en) | Arginine silicate inositol for improving cognitive function | |
| WO2018154118A3 (en) | Aromatic compounds which enhance notch signaling, for use in therapy | |
| MX2025015490A (es) | Compuestos | |
| WO2024054688A3 (en) | Therapeutic combinations for movement disorders | |
| MX2024014447A (es) | Compuestos | |
| TW200724532A (en) | Pyrimidinecarboxylic acid derivatives and their use | |
| WO2004042389A3 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) | |
| WO2006023452A3 (en) | Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases | |
| WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| MX2025015493A (es) | Compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED Effective date: 20240705 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251222 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251222 |